Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

Inclusion Criteria:

   - Histological or cytological diagnosis of Large B-cell Lymphoma (LBCL) or Follicular
   Lymphoma.

   - Relapse or refractory disease after at least 2 lines of chemotherapy

   - At least 1 measurable lesion at time of screening.

   - Eastern Cooperative Oncology Group Performance Status of 0 or 1.

   - Adequate hematological, renal, liver, pulmonary, and cardiac functions.

Exclusion Criteria:

   - Current or history of central nervous system (CNS) lymphoma.

   - Clinically significant CNS dysfunction.

   - ASCT within last 6 weeks or allogeneic HSCT within last 3 months prior to ALLO-647.

   - Prior treatment with anti-CD19 therapy, any gene therapy, any genetically modified
   cell therapy or adoptive T cell therapy

   - Systemic anticancer therapy within 2 weeks prior to study entry.

   - On-going treatment with immunosuppressive agents.

   - Active acute or chronic graft versus host disease (GvHD), or GvHD requiring
   immunosuppressive treatment within 4 weeks of enrollment.

   - Any form of primary or acquired immunodeficiency (e.g., severe combined
   immunodeficiency disease).

   - Current thyroid disorder (including hyperthyroidism), except for subjects with
   hypothyroidism controlled on a stable dose of hormone replacement therapy.

   - Patients unwilling to participate in an extended safety monitoring period